Marlborough, Mass.-based Boston Scientific Corp. acquired EMcision Ltd., a privately held U.K.-based medical device company that focuses on treating cancer.
The acquisition gains Boston Scientific access to EMcision's Habib EndoHPB probe for partial destruction of tumors in the bile duct and the head of the pancreas in patients with pancreaticobiliary cancers. The Habib EndoHPB probe has received U.S. Food and Drug Administration clearance and the EU's CE marking. Boston Scientific develops medical devices for patients with heart, lung and digestive tract diseases.
The transaction is expected to have no impact on Boston Scientific's EPS in 2018. The company did not disclose specific terms of the deal.
EMcision also manufactures catheters for patients with cancers that are difficult to treat and for whom surgery is not an option.
Pancreaticobiliary cancers, for which there are limited treatment options, account for nearly a million deaths annually worldwide.
